Savara Inc. Stock
Savara Inc. Stock
Savara Inc. took a tumble today and lost -€0.120 (-3.030%).
The community is currently still undecided about Savara Inc. with 1 Buy predictions and 0 Sell predictions.
As a result the target price of 8 € shows a very positive potential of 92.31% compared to the current price of 4.16 € for Savara Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Savara Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Savara Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Savara Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Savara Inc. | -3.030% | -5.882% | -6.726% | 152.121% | -2.804% | 163.291% | -56.362% |
| Gritstone Oncology Inc | 7.730% | -1.832% | -69.325% | -65.197% | -59.634% | -90.013% | - |
| Avid Bioservices Inc | 0.700% | 13.492% | 11.719% | -54.167% | 17.213% | -59.605% | 68.991% |
| Pacira Pharmaceuticals | 0.830% | 1.681% | -7.634% | -39.196% | -18.792% | -53.010% | -30.818% |
News
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On March 21
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending